Acute Decompensated Heart Failure Update

Overview

Journal Curr Cardiol Rev

Publisher Bentham Science Publishers

Specialty Cardiology & Vascular Diseases

Date 2013 Nov 21

PMID 24251454

Citations 26

Authors

John R Teerlink

Khalid Alburikan

Marco Metra

Jo E Rodgers

Affiliations

Soon will be listed here.

Abstract

Acute decompensated heart failure (ADHF) continues to increase in prevalence and is associated with substantial mortality and morbidity including frequent hospitalizations. The American Heart Association is predicting that more than eight million Americans will have heart failure by 2030 and that the total direct costs associated with the disease will rise from $21 billion in 2012 to $70 billion in 2030. The increase in the prevalence and cost of HF is primarily the result of shifting demographics and a growing population. Although many large, randomized, controlled clinical trials have been conducted in patients with chronic heart failure, it was not until recently that a growing number of studies began to address the management of ADHF. It is the intent of this review to update the clinician regarding the evaluation and optimal management of ADHF.

Citing Articles

Deterioration Patterns in Patients Admitted for Severe COPD Exacerbation.

Correa-Gutierrez C, Ji Z, Dominguez-Zabaleta I, Plaza-Hoz J, Gorrochategui-Mendigain I, Lopez-de-Andres A Diseases. 2024; 12(11).

PMID: 39589957 PMC: 11593009. DOI: 10.3390/diseases12110283.

Noninvasive biometric monitoring technologies for patients with heart failure.

Arriola-Montenegro J, Mutirangura P, Akram H, Tsangaris A, Koukousaki D, Tschida M Heart Fail Rev. 2024; .

PMID: 39436486 DOI: 10.1007/s10741-024-10441-7.

Temporal trends in acute decompensated heart failure outcomes: A single-center 11-year retrospective analysis.

Marcus G, Najjar M, Monayer A, Orbach A, Maymon S, Kalmanovich E Int J Cardiol Cardiovasc Risk Prev. 2024; 22:200306.

PMID: 39055966 PMC: 11269909. DOI: 10.1016/j.ijcrp.2024.200306.

The Use of Drugs that Should be Avoided or Used with Caution in Patients Hospitalized for Acute Decompensated Heart Failure.

Sheikh-Taha M Am J Cardiovasc Drugs. 2024; 24(5):685-691.

PMID: 38976171 DOI: 10.1007/s40256-024-00663-3.

Predicting One-Year Mortality after Discharge Using Acute Heart Failure Score (AHFS).

Magaldi M, Nogue E, Molinari N, De Luca N, Dupuy A, Leclercq F J Clin Med. 2024; 13(7).

PMID: 38610783 PMC: 11012877. DOI: 10.3390/jcm13072018.

References

Metra M, Bettari L, Pagani F, Lazzarini V, Lombardi C, Carubelli V . Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. Clin Res Cardiol. 2012; 101(8):663-72. DOI: 10.1007/s00392-012-0441-5. View

Uretsky B, Young J, Shahidi F, Yellen L, Harrison M, Jolly M . Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol. 1993; 22(4):955-62. DOI: 10.1016/0735-1097(93)90403-n. View

OConnor C, Abraham W, Albert N, Clare R, Stough W, Gheorghiade M . Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008; 156(4):662-73. DOI: 10.1016/j.ahj.2008.04.030. View

Binanay C, Califf R, Hasselblad V, OConnor C, Shah M, Sopko G . Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005; 294(13):1625-33. DOI: 10.1001/jama.294.13.1625. View

Peacock W, Braunwald E, Abraham W, Albert N, Burnett J, Christenson R . National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. J Am Coll Cardiol. 2010; 56(5):343-51. DOI: 10.1016/j.jacc.2010.03.051. View

Hasenfuss G, Teerlink J . Cardiac inotropes: current agents and future directions. Eur Heart J. 2011; 32(15):1838-45. DOI: 10.1093/eurheartj/ehr026. View

Thackray S, Easthaugh J, Freemantle N, Cleland J . The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail. 2002; 4(4):515-29. DOI: 10.1016/s1388-9842(02)00041-7. View

Felker G, Lee K, Bull D, Redfield M, Stevenson L, Goldsmith S . Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011; 364(9):797-805. PMC: 3412356. DOI: 10.1056/NEJMoa1005419. View

Yancy C, Jessup M, Bozkurt B, Butler J, Casey Jr D, Drazner M . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776. View

10.

Fonarow G, Adams Jr K, Abraham W, Yancy C, Boscardin W . Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005; 293(5):572-80. DOI: 10.1001/jama.293.5.572. View

11.

Lindenfeld J, Albert N, Boehmer J, Collins S, Ezekowitz J, Givertz M . HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010; 16(6):e1-194. DOI: 10.1016/j.cardfail.2010.04.004. View

12.

Ahmed A, Gambassi G, Weaver M, Young J, Wehrmacher W, Rich M . Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. Am J Cardiol. 2007; 100(2):280-4. PMC: 2685183. DOI: 10.1016/j.amjcard.2007.02.099. View

13.

Konstam M, Gheorghiade M, Burnett Jr J, Grinfeld L, Maggioni A, Swedberg K . Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007; 297(12):1319-31. DOI: 10.1001/jama.297.12.1319. View

14.

Gattis W, OConnor C . Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am J Cardiol. 2004; 93(9A):74B-6B. DOI: 10.1016/j.amjcard.2004.01.019. View

15.

Felker G, Hasselblad V, Tang W, Hernandez A, Armstrong P, Fonarow G . Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. Eur J Heart Fail. 2012; 14(11):1257-64. DOI: 10.1093/eurjhf/hfs110. View

16.

Hasselblad V, Stough W, Shah M, Lokhnygina Y, OConnor C, Califf R . Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007; 9(10):1064-9. PMC: 3127394. DOI: 10.1016/j.ejheart.2007.07.011. View

17.

Abraham W, Adams K, Fonarow G, Costanzo M, Berkowitz R, Lejemtel T . In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005; 46(1):57-64. DOI: 10.1016/j.jacc.2005.03.051. View

18.

Costanzo M, Guglin M, Saltzberg M, Jessup M, Bart B, Teerlink J . Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007; 49(6):675-83. DOI: 10.1016/j.jacc.2006.07.073. View

19.

Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A . Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol. 2013; 61(8):820-9. DOI: 10.1016/j.jacc.2012.11.054. View

20.

Packer M, Gheorghiade M, Young J, Costantini P, Adams K, Cody R . Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993; 329(1):1-7. DOI: 10.1056/NEJM199307013290101. View